Last updated on February 2019

A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3K-delta Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

 

Clinical Study Identifier: TX203807

Contact Investigators or Research Sites near you

Start Over

Calvary North Adelaide Hospital

North Adelaide, Australia
3.98miles
  Connect »

ROYAL ADELAIDE HOSPITAL

Adelaide, Australia
5.29miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.